Cellect Biotechnology Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Cellect Biotechnology Ltd. (not Quoin Pharmaceuticals) on October 27, 2016, for the month of October 2016. The filing serves as a report of a material corporate event regarding executive leadership changes.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and contains no financial performance data.
Material Changes
- Resignation: Mr. Ronen Twito, Chief Financial Officer and Deputy CEO, has resigned to pursue other interests.
- Appointment: Mr. Eyal Leibovitz has been appointed as the new Chief Financial Officer, effective January 1, 2017.
- Transition: Mr. Twito will remain with the company for a four-month notice period to assist with the transition.
Management Commentary and Outlook
CEO Dr. Shai Yarkoni stated that Mr. Twito was a valuable member of the team who led the company to significant achievements. The company expressed sadness at his departure and welcomed Mr. Leibovitz. Mr. Leibovitz brings over 27 years of experience in senior management, finance, and M&A, including leading capital raises and the sale of N-trig to Microsoft during his tenure at Kamada Ltd.
Key Facts for Investor Verification
- Verify the effective date of the new CFO's appointment (January 1, 2017).
- Confirm the duration of the transition period for the outgoing CFO (four months).
- Review the new CFO's background regarding his experience with NASDAQ/NYSE listed companies.
- Note that this filing contains no financial results; investors should refer to the most recent Form 20-F for financial data.